Bruno R - Search Results

1

Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First-Line Gastric Cancer and Elevated Plasma VEGF-A.

Han K, Claret L, Piao Y, Hegde P, Joshi A, Powell JR, Jin J, Bruno R. Han K, et al. Among authors: bruno r. CPT Pharmacometrics Syst Pharmacol. 2016 Jul;5(7):352-8. doi: 10.1002/psp4.12064. Epub 2016 Jul 12. CPT Pharmacometrics Syst Pharmacol. 2016. PMID: 27404946 Free PMC article.

2

Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects.

Sun YN, Lu JF, Joshi A, Compton P, Kwon P, Bruno RA. Sun YN, et al. J Clin Pharmacol. 2005 Apr;45(4):468-76. doi: 10.1177/0091270004272731. J Clin Pharmacol. 2005. PMID: 15778428

3

Modeling and simulation of sexual activity daily diary data of patients with female sexual arousal disorder treated with sildenafil citrate (Viagra).

Claret L, Cox EH, McFadyen L, Pidgen A, Johnson PJ, Haughie S, Boolell M, Bruno R. Claret L, et al. Among authors: bruno r. Pharm Res. 2006 Aug;23(8):1756-64. doi: 10.1007/s11095-006-9007-4. Pharm Res. 2006. PMID: 16841199 Clinical Trial.

4

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Lu JF, et al. Among authors: bruno r. Cancer Chemother Pharmacol. 2008 Oct;62(5):779-86. doi: 10.1007/s00280-007-0664-8. Epub 2008 Jan 19. Cancer Chemother Pharmacol. 2008. PMID: 18205003

5

On the use of change in tumor size to predict survival in clinical oncology studies: toward a new paradigm to design and evaluate phase II studies.

Bruno R, Claret L. Bruno R, et al. Clin Pharmacol Ther. 2009 Aug;86(2):136-8. doi: 10.1038/clpt.2009.97. Clin Pharmacol Ther. 2009. PMID: 19621009

6

Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.

Claret L, Girard P, Hoff PM, Van Cutsem E, Zuideveld KP, Jorga K, Fagerberg J, Bruno R. Claret L, et al. Among authors: bruno r. J Clin Oncol. 2009 Sep 1;27(25):4103-8. doi: 10.1200/JCO.2008.21.0807. Epub 2009 Jul 27. J Clin Oncol. 2009. PMID: 19636014

7

A modeling and simulation framework to support early clinical drug development decisions in oncology.

Bruno R, Lu JF, Sun YN, Claret L. Bruno R, et al. J Clin Pharmacol. 2011 Jan;51(1):6-8. doi: 10.1177/0091270010376970. Epub 2010 Jul 13. J Clin Pharmacol. 2011. PMID: 20628172 No abstract available.

8

Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.

Lu JF, Claret L, Sutjandra L, Kuchimanchi M, Melara R, Bruno R, Sun YN. Lu JF, et al. Among authors: bruno r. Cancer Chemother Pharmacol. 2010 Nov;66(6):1151-8. doi: 10.1007/s00280-010-1456-0. Epub 2010 Sep 25. Cancer Chemother Pharmacol. 2010. PMID: 20872145

9

Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer.

Claret L, Lu JF, Sun YN, Bruno R. Claret L, et al. Among authors: bruno r. Cancer Chemother Pharmacol. 2010 Nov;66(6):1141-9. doi: 10.1007/s00280-010-1449-z. Epub 2010 Sep 25. Cancer Chemother Pharmacol. 2010. PMID: 20872147

10

Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer.

Frances N, Claret L, Bruno R, Iliadis A. Frances N, et al. Among authors: bruno r. Cancer Chemother Pharmacol. 2011 Dec;68(6):1413-9. doi: 10.1007/s00280-011-1628-6. Epub 2011 Apr 8. Cancer Chemother Pharmacol. 2011. PMID: 21476101

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,856 results

Search Page

Filters